Takeda Pharmaceutical Co. Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Julie So-Young Kim
- Full Time Employees
- 47,029
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1-1, Nihonbashi-Honcho 2-chome Osaka OS Japan 103-8668
- IPO Date
- May 16, 1949
- Website
- takeda.com
- Similar Companies
- Business
- Takeda Pharmaceutical Company Limited is a global biopharmaceutical company primarily engaged in the research, development, manufacturing, and marketing of pharmaceutical products. Its core product portfolio includes prescription pharmaceuticals across therapeutic areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. Takeda offers branded prescription medicines, vaccines, and over-the-counter products with notable brands in oncology (including ADCETRIS®, NINLARO®, and ALUNBRIG®), gastroenterology, and central nervous system treatments. The company operates worldwide, with extensive geographic reach across Japan, the Americas, Europe, Asia Pacific, and emerging markets. Headquartered in Tokyo, Japan, Takeda was founded in 1781 and has grown into a leading global pharmaceutical player. It serves a diverse customer base including healthcare professionals, hospitals, and specialized clinics. Recent major company developments include strategic partnerships, acquisitions, and product launches aimed at strengthening its R&D pipeline and expanding its global footprint. In the last 1-2 years, Takeda has focused on innovative therapies and biologics, including expanding presence in gene therapy and rare diseases. It has launched new treatments and formed alliances to enhance its capabilities in oncology and rare diseases. The company continues to invest significantly in its global manufacturing and distribution infrastructure to support growth and meet evolving healthcare needs. Takeda remains a public company, listed as 4502.T, and continues to execute on strategic initiatives to drive sustainable growth in the biopharmaceutical industry.
Company News
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
Takeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust Pipeline
Critical Contrast: ProPhase Labs (NASDAQ:PRPH) & Takeda Pharmaceutical (NYSE:TAK)
Takeda Pharmaceutical (NYSE:TAK) vs. RYTHM (NASDAQ:RYM) Financial Survey
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
Roche proposes former Takeda CEO for board seat
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
Takeda Pharmaceutical (NYSE:TAK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Financial Contrast
Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Best Value Stocks to Buy for September 14th
Best Income Stocks to Buy for September 14th
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
Critical Survey: ABVC BioPharma (NASDAQ:ABVC) vs. Takeda Pharmaceutical (NYSE:TAK)